NARILIS seminar given by Dr. Nicolas JONCKHEERE, Research Center Jean-Pierre Aubert, Lille

  • When Apr 03, 2019 from 11:00 AM to 12:00 PM (Europe/Brussels / UTC200)
  • Where UNamur, BN01 auditorium
  • Add event to calendar iCal

NARILIS has the great pleasure to invite you to a seminar given by


Senior scientist at the

Research Center Jean-Pierre Aubert, Lille

Mucins, epithelial differentiation and carcinogenesis team, led by Dr Isabelle VAN SEUNINGEN

"Role of MUC4 mucin and ErbB2 oncogenic receptor in pancreatic carcinogenesis and chemoresistance"

Pancreatic Ductal Adenocarcinoma (PDAC) cancer is the 4th leading cause of death by cancer in the world with an extremely low survival rate (6 months) and a short survival curve at 5 years (3%). The lack of early diagnosis and efficient therapy leads to this dramatic outcome. It is urgent to develop new diagnostic and/or prognostic tools for the clinicians in order to propose better healthcare management of the disease. Moreover, identification of new molecular targets by deciphering the molecular mechanisms underlying the disease will allow the development of both new therapeutic tools and new therapeutic approaches to treat the disease.

The membrane-bound mucin MUC4 is not expressed in normal pancreas whereas it is expressed in the earliest precursor lesion PanIN1A and its expression increases toward adenocarcinoma. Moreover, MUC4 is a target gene of TGF-b pathway in pancreatic cancer cells and is the partner of oncogenic receptor ErbB2. Thus, MUC4 could be a major actor of pancreatic carcinogenesis and a promising therapeutic target.

Nicolas Jonckheere's research project aims to understand the roles of MUC4 and ErbB2 in pancreatic carcinogenesis. He uses a triple (in vitro, in vivo and ex vivo) approach to decipher the role of these genes.